Valuation: Cipher Pharmaceuticals Inc.

Market Cap 426M 303M 265M 245M 226M 29.09B 433M 2.92B 1.14B 14.24B 1.14B 1.11B 49.05B P/E 2026 *
13.7x
P/E 2027 * 12.1x
Enterprise Value 426M 303M 265M 245M 226M 29.09B 433M 2.92B 1.14B 14.24B 1.14B 1.11B 49.05B EV / Sales 2026 *
5.82x
EV / Sales 2027 * 5.04x
Free-Float
57.64%
Yield 2026 *
-
Yield 2027 * -
1 day-0.83%
1 week-3.29%
Current month+0.54%
1 month+2.76%
3 months-13.92%
6 months+7.71%
Current year+11.29%
1 week 16.64
Extreme 16.64
17.22
1 month 15.93
Extreme 15.93
17.8
Current year 14.2
Extreme 14.2
20.56
1 year 11.98
Extreme 11.98
20.56
3 years 3.35
Extreme 3.35
20.56
5 years 1.43
Extreme 1.43
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap.
06-23Option

Chief Executive Officer

78,007 0.3072%
06-23Option

Chief Executive Officer

-2,500 0.0098%
06-23Option

Director

-1,149 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-3.29%+30.43%+376.14% 303M
-2.48%-6.72%+44.19%+156.43% 1,028B
-1.52%-5.01%+61.87%+58.79% 611B
-1.30%-3.88%+27.81%+79.97% 432B
+0.03%-2.15%+28.51%+22.18% 323B
-0.65%-3.26%+26.80%+43.43% 277B
+0.51%-12.54%+18.65%+22.10% 257B
+0.36%-0.63%-25.86%-40.09% 217B
-1.44%-3.49%+19.60%+56.20% 192B
-1.04%-4.63%+16.01%+68.47% 161B
Average -0.27%-5.04%+24.80%+84.36% 349.86B
Weighted average by Cap. -0.20%-5.52%+33.57%+77.01%

Financials

2026 *2027 *
Net sales 73.13M 52.03M 45.47M 42.03M 38.83M 5B 74.45M 501M 197M 2.45B 195M 191M 8.43B 84.52M 60.14M 52.55M 48.58M 44.88M 5.78B 86.05M 579M 227M 2.83B 226M 221M 9.74B
Net income 30.44M 21.66M 18.93M 17.5M 16.17M 2.08B 30.99M 209M 81.87M 1.02B 81.35M 79.56M 3.51B 36.1M 25.68M 22.44M 20.75M 19.17M 2.47B 36.75M 247M 97.07M 1.21B 96.46M 94.33M 4.16B
Net Debt - -
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-07-14 $16.76 -0.83% 13,529
26-07-13 $16.90 -1.34% 17,900
26-07-10 $17.13 +1.18% 12,338
26-07-09 $16.93 -0.47% 5,307
26-07-08 $17.01 -1.85% 3,564
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.76CAD
Average target price
20.64CAD
Spread / Average Target
+23.14%

Quarterly revenue - Rate of surprise